Zenas BioPharma, Inc. 8-K

What Happened

• Zenas BioPharma, Inc. announced its quarterly financial results for the quarter ended March 31, 2026 via a press release dated May 13, 2026 (Exhibit 99.1 to the 8‑K).
• At the Company’s Annual Meeting on May 11, 2026, Tomas Kiselak did not stand for re‑election and his term ended, resulting in his resignation from the board and a reduction in the board size by one.

Key Details

• Press release reporting Q1 2026 results furnished as Exhibit 99.1 to the Form 8‑K (the exhibit is furnished, not “filed,” per the filing).
• Director election votes (Class II directors, three‑year terms expiring 2029):
  • James Boylan: For 44,083,930; Against 4,121,508; Abstain 2,499; Broker non‑votes 4,458,184.
  • Patrick Enright: For 44,253,715; Against 3,951,474; Abstain 2,748; Broker non‑votes 4,458,184.
• Auditor ratification: Ernst & Young LLP reappointed as independent registered public accounting firm for fiscal 2026 — For 52,654,975; Against 7,650; Abstain 3,496.
• Board change: Tomas Kiselak’s resignation effective at the conclusion of the May 11, 2026 Annual Meeting.

Why It Matters

• The press release contains the company’s latest quarterly earnings and operating results (revenue, expenses, cash/liquidity and other metrics), which investors should review to assess near‑term performance and runway.
• The board change and the reappointment of Ernst & Young LLP are governance items investors track for oversight continuity; the two Class II nominees were elected to three‑year terms through 2029.